PROJECT

Projects

Summary of Investment Information

Project Number

40144

Company Name

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.

Date SPI Disclosed

Feb 7, 2018

Country

Mexico

Region

Latin America and the Caribbean

Projected Board Date

Mar 12, 2018

Environmental Category

B - Limited

Status

Active

Last Updated Date

Jul 7, 2018

Department

Regional Industry - MAS LAC

Industry

Health, Education and Life Sciences

Previous Events

Approved : Apr 25, 2018
Signed : May 20, 2018
Invested : Jul 2, 2018

Sector

Pharmaceuticals and Medicine

Project Description

Founded in 1996, Genomma Lab Internacional S.A.B. de C.V. ("Genomma" or the “Company”) is a Mexico-based, pharmaceutical company listed in the Mexican Stock Exchange with a presence in 18 countries across Latin America, and in the U.S.. It is focused on the marketing, distribution and sales of over-the-counter (“OTC”) or non-prescription medicines and personal care products. Genomma uses third-party contract manufacturers to manufacture its products, 90 percent of which are manufactured in Mexico).  

 

The purpose of IFC’s proposed financing is to support Genomma’s approximately US$232 million expansion plan over the next 2 years which includes the construction of Genomma’s first manufacturing facility in the state of Mexico, debt refinancing, and other capital expenditures (the “Project”). 

Associated Advisory Engagement

 IFC is in early discussions with the Company to potentially advise Genomma in the implementation of green building elements to achieve the Excellence in Design for Greater Efficiencies (EDGE) certification, which would be the first pharmaceutical manufacturing plant certified under EDGE worldwide.

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation